美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

35.56

-0.2200-0.61%

成交量：32.42萬

成交額：1,155.19萬

市值：2.80億

市盈率：- -

高：35.97

開：35.90

低：35.51

收：35.78

52周最高：36.14

52周最低：25.85

股本：787.00萬

流通股本：787.00萬

量比：1.20

換手率：4.12%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金

德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白

優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者

向「領跑者」跨越！中國雙抗藥物再迎高光時刻

每日经济新闻

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ORR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":35.56,"timestamp":1769198589655,"preClose":35.78,"halted":0,"volume":324154,"delay":0,"changeRate":-0.006148686416992701,"floatShares":7870000,"shares":7870000,"eps":0,"marketStatus":"交易中","change":-0.22,"latestTime":"01-23 15:04:35 EST","open":35.9,"high":35.97,"low":35.51,"amount":11551883.877695998,"amplitude":0.012856,"askPrice":35.59,"askSize":200,"bidPrice":35.56,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1769202000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.78,"sharesOutstanding":7870000,"nav":35.29,"aum":277732300,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":37.69,"preClose":35.78,"latestTime":"09:24 EST","volume":204,"amount":7240.65972,"timestamp":1769178255025,"change":1.91,"changeRate":0.053382,"amplitude":0.064002},"postHourTrading":{"tag":"盘后","latestPrice":36,"preClose":35.78,"latestTime":"19:27 EST","volume":477,"amount":17155.312,"timestamp":1769128066731,"change":0.22,"changeRate":0.006149,"amplitude":0.006149},"volumeRatio":1.202478,"impliedVol":0.0146,"impliedVolPercentile":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":7870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.202478,"shares":7870000,"dividePrice":0,"high":35.97,"amplitude":0.012856,"preClose":35.78,"low":35.51,"week52Low":25.85,"pbRate":"--","week52High":36.135,"institutionHeld":0,"latestPrice":35.56,"committee":-0.333333,"eps":0,"divideRate":0,"volume":324154,"delay":0,"ttmEps":0,"open":35.9,"prevYearClose":34.16,"prevWeekClose":35.75,"prevMonthClose":34.16,"prevQuarterClose":34.16,"fiveDayClose":35.44,"twentyDayClose":34.24,"sixtyDayClose":32.042},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605034473","title":"優赫得在華拓展第六個適應症，去年上半年銷售額突破22億美金","url":"https://stock-news.laohu8.com/highlight/detail?id=2605034473","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605034473?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 17:13","pubTimestamp":1769159628,"startTime":"0","endTime":"0","summary":"2024 年全球已获批上市的 17 款 ADC 药物合计销售额达百亿美金，其中第一三共的德曲妥珠单抗表现尤为突出，2024 年销售额达到 34.8 亿美元、同比增长 52%。根据阿斯利康2025年上半年财报，其自身销售额为12.6亿美元，增长38%；包括合作伙伴第一三共报告的销售额在内，总销售额为22.9亿美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1769159310955231385","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ADC","OS","BK4231","ORR","BK4097","PFS","BK4195","BK4211","BK4080"],"gpt_icon":0},{"id":"2605989254","title":"德曲妥珠單抗胃癌新適應證獲批，填補臨牀治療空白","url":"https://stock-news.laohu8.com/highlight/detail?id=2605989254","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605989254?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 19:18","pubTimestamp":1769080687,"startTime":"0","endTime":"0","summary":"由阿斯利康和第一三共共同开发与商业化的优赫得（英文商品名：Enhertu，通用名：注射用德曲妥珠单抗）今天获中国国家药品监督管理局（NMPA）批准，本品单药适用于治疗既往接受过一种含曲妥珠单抗治疗方案的局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者。德曲妥珠单抗是由阿斯利康和第一三共联合开发和商业化的一款独特设计靶向HER2的抗体偶联药物（ADC）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627553572.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4080","BK4195","BK4231","OS","BK4097","BK4211","ORR","ADC","PFS"],"gpt_icon":0},{"id":"2605495703","title":"優赫得®在華獲批治療既往接受過一種含曲妥珠單抗治療方案的局部晚期或轉移性HER2陽性成人胃或胃食管結合部腺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605495703","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605495703?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 18:38","pubTimestamp":1769078280,"startTime":"0","endTime":"0","summary":"研究显示，对于局部晚期或转移性HER2阳性成人胃或胃食管结合部腺癌患者，与雷莫西尤单抗+紫杉醇相比，德曲妥珠单抗带来具有显著统计学差异和临床意义的总生存期改善。自一年多前首次在中国获批用于HER2阳性局部晚期或转移性胃癌以来，德曲妥珠单抗仅可用于三线及后线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4868984_ZH68984_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["OS","LU0792757196.USD","LU2237443895.HKD","LU0320765992.SGD","BK4579","CSCO","LU1571399168.USD","LU1244550577.SGD","LU0234572021.USD","IE00BKVL7J92.USD","BK4195","LU1221951129.SGD","LU1221951046.USD","SG9999015945.SGD","BK4527","LU1046421795.USD","LU1196500208.SGD","ADC","LU1066053197.SGD","LU1929549753.HKD","BK4080","LU1066051498.USD","LU2237443549.SGD","LU2237443622.USD","LU1244550494.USD","SG9999015978.USD","IE000M9KFDE8.USD","LU2247934214.USD","BK4097","LU2506951958.HKD","LU0868494617.USD","LU1880398554.USD","LU0109394709.USD","LU1894683348.USD","ORR","IE00BFMHRM44.USD","PFS","BK4560","LU2506951875.HKD","SG9999001440.SGD","AZN","BK4585","LU2417539215.USD","BK4231","LU2462157665.USD","LU2506952097.USD","LU1880398471.USD","BK4612","LU2237443382.USD","BK4588"],"gpt_icon":0},{"id":"2603130816","title":"向「領跑者」跨越！ 中國雙抗藥物再迎高光時刻","url":"https://stock-news.laohu8.com/highlight/detail?id=2603130816","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603130816?lang=zh_tw&edition=fundamental","pubTime":"2026-01-14 20:14","pubTimestamp":1768392877,"startTime":"0","endTime":"0","summary":"2026年1月12日，第四十四届摩根大通医疗健康大会在美国旧金山召开，当全球生物医药界的目光聚焦于该会议时，大洋彼岸的中国接连传来重磅消息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601143619177920.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601143619177920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0634319403.HKD","BK4585","LU0348825331.USD","LU1720050803.USD","PFS","LU0053666078.USD","LU1794554557.SGD","LU1961090484.USD","LU0210528500.USD","BK4007","BK4195","LU0417516571.SGD","LU0540923850.HKD","LU2476274308.USD","LU0348827113.USD","IE00BPRC5H50.USD","LU0417516738.SGD","09926","LU2399975544.HKD","IE00B543WZ88.USD","LU1829250122.USD","LU1969619763.USD","BK1583","GSK.UK","LU2476274720.SGD","BK4107","LU0417516902.SGD","BMS","ORR","L","LU0348766576.USD","LU2778985437.USD","LU0348784397.USD","BK1574","LU0348783233.USD","GSK","LU2488822045.USD","BK4588","BK4532","BK4211","IE00B5MMRT66.SGD","LU2487616109.SGD","LU0348767384.USD","LU0348735423.USD","LU0561508036.HKD","BK1161","09995","LU2328871848.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}